Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: Results of Markov modelling in a UK setting

European Journal of Heart Failure

Volumn 13, Issue 6, 2011, Pages 681-689

  Cowie, Martin R ^a   Cure, Sandrine ^b   Bianic, Florence ^b   McGuire, Alistair ^c   Goodall, Gordon ^d   Tavazzi, Luigi ^e  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b i3 Innovus   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d ABBOTT LABORATORIES   (United States)

^e GVM Hospitals of Care and Research   (Italy)

Author keywords

Chronic heart failure; Cost effectiveness; Omega 3 polyunsaturated fatty acids

Indexed keywords

OMEGA 3 FATTY ACID ESTER;

ARTICLE; CARDIAC PATIENT; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEART FAILURE; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNITED KINGDOM;

AGED; CHRONIC DISEASE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FATTY ACIDS, OMEGA-3; FEMALE; GREAT BRITAIN; HEART FAILURE; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; STATE MEDICINE; TREATMENT OUTCOME;

EID: 79957827590     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr023     Document Type: Article

References (28)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. Eur Heart J 1997;18:208-225. (Pubitemid 27107582)
2. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283-291. (Pubitemid 32895835)
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402. (Pubitemid 35239711)
4. Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC, McDonagh TA, Cowie MR. Improving survival in the 6 months after diagnosis of heart failure in the past decade: population-based data from the UK. Heart 2009;95:1851-1856.
5. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Calmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515-523.
6. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-1876. (Pubitemid 35398056)
7. Cowie MR, Fox KF, Wood DA, Metcalfe C, Thompson SG, Coats AJ, Poole-Wilson PA, Sutton GC. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002;23:877-885. (Pubitemid 34717423)
8. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, va Gilst WH, Widimisky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24: 442-63. (Pubitemid 36286187)
9. Hospital episode statistics (HES) online. http://www.hesonline.nhs.uk (May 2010).
10. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230.
11. Gissi-Prevenzione Investigators. Dietary supplementation with n-3 polyunsatu-rated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455.
12. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51. (Pubitemid 46134956)
13. The NHS Information centre for Health and Social care. National Heart Failure Audit Second report for the audit period between April 2008 and March 2009. http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/ NHS-National-Heart-Failure-Audit-09-INTERACTIVE.pdf
14. Quilici S, Martin M, McGuire A, Zoellner Y. A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients. Int J Clin Pract 2006;60:922-932. (Pubitemid 44082283)
15. Lamotte M, Annemans L, Kawalec P, Zoellner Y. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Pharmacoeconomics 2006;24:783-795. (Pubitemid 44232106)
16. Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'In-farto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001;19:411-420. (Pubitemid 32319934)
17. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
18. National Clinical Guideline Centre. Chronic Heart Failure: the Management of Chronic Heart Failure in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre 2010.
19. Dijkstra SC, Brouwer IA, van Rooij FJ, Hofman A, Witteman JC, Geleijnse JM. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail 2009;11:922-928.
20. Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005;45:2015-2021. (Pubitemid 40814125)
21. Rischio & Prevenzione Investigators. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials. 2010;11:68.
22. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32.
23. The ASCEND Trial (A Study of Cardiovascular Events iN Diabetes).http://www. ctsu.ox.ac.uk/ascend/
24. Joint Formulary Committee. British National Formulary. 59 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
25. Personal Social Services Research Unit. Unit costs of health & social care. 2008.
26. Department of Health. Reference Costs 2007-08. London: Department of Health; 2009.
27. National Collaborating Centre for Chronic Conditions. Stroke: National Clinical Guideline for Diagnosis and Initial Management of Acute Stroke and Transient Ischaemic Attack (TIA). London: Royal College of Physicians; 2008.
28. Patel H, Shafazand M, Ekman I, Hojgard S, Swedberg K, Schaufelberger M. Home care as an option in worsening chronic heart failure-a pilot study to evaluate feasibility, quality adjusted life years and cost-effectiveness. Eur J Heart Fail 2008; 10:675-681.